Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 29–36 | Cite as

CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer’s Disease

  • Jeremy Koppel
  • Valerie Vingtdeux
  • Philippe Marambaud
  • Cristina d’Abramo
  • Heidy Jimenez
  • Mark Stauber
  • Rachel Friedman
  • Peter Davies
Research Article

Abstract

The endocannabinoid CB2 receptor system has been implicated in the neuropathology of Alzheimer’s disease (AD). In order to investigate the impact of the CB2 receptor system on AD pathology, a colony of mice with a deleted CB2 receptor gene, CNR2, was established on a transgenic human mutant APP background for pathological comparison with CB2 receptor-sufficient transgenic mice. J20 APP (PDGFB-APPSwInd) mice were bred over two generations with CNR2−/− (Cnr2tm1Dgen / J) mice to produce a colony of J20 CNR2+I+ and J20 CNR2−/− mice. Seventeen J20 CNR2+I+ mice (12 females, 5 males) and 16 J20 CNR2−/− mice (11 females, 5 males) were killed at 12 months, and their brains were interrogated for AD-related pathology with both biochemistry and immunocytochemistry (ICC). In addition to amyloid-dependent endpoints such as soluble Aβ production and plaque deposition quantified with 6E10 staining, the effect of CB2 receptor deletion on total soluble mouse tau production was assayed by using a recently developed high-sensitivity assay. Results revealed that soluble Aβ42 and plaque deposition were significantly increased in J20 CNR2−/− mice relative to CNR2+/+ mice. Microgliosis, quantified with ionized calcium-binding adapter molecule 1 (Iba-1) staining, did not differ between groups, whereas plaque associated microglia was more abundant in J20 CNR2−/− mice. Total tau was significantly suppressed in J20 CNR2−/− mice relative to J20 CNR2+/+ mice. The results confirm the constitutive role of the CB2 receptor system both in reducing amyloid plaque pathology in AD and also support tehpotential of cannabinoid therapies targeting CB2 to reduce Aβ; however, the results suggest that interventions may have a divergent effect on tau pathology.

Notes

Acknowledgments

We would like to acknowledge the collaborative support of Heather Bradshaw and Ken Mackie of Indiana University.

References

  1. 1.
    Dickson DW. (1997) Neuropathological diagnosis of Alzheimer’s disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging. 18:S21–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Prinz M, Priller J, Sisodia SS, Ransohoff RM. (2011) Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 14:1227–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Streit WJ, Mrak RE, Griffin WS. (2004) Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation. 1: 14.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Streit WJ. (2004) Microglia and Alzheimer’s disease pathogenesis. J. Neurosci. Res. 77:1–8.CrossRefGoogle Scholar
  5. 5.
    Thiebot M-H, Chaperon F, Fride E, Onaivi ES (2006) Chapter 13, Behavioral Effects of Endocannabinoids. In: Endocannabinoids: the Brain and Body’s Marijuana and Beyond. Onaivi ES, Suguira T, Di Marzo V. (eds.) CRR Press, Taylor & Francis Group, Boca Raton, FL. pp. 303–348.Google Scholar
  6. 6.
    Lunn CA, Reich EP, Bober L. (2006) Targeting the CB2 receptor for immune modulation. Expert Opin. Ther. Targets. 10:653–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Grunblatt E, et al. (2007) Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease. J. Alzheimers Dis. 12:291–311.CrossRefGoogle Scholar
  8. 8.
    Grunblatt E, et al. (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer’s disease. J. Alzheimers Dis. 16:627–34.CrossRefGoogle Scholar
  9. 9.
    D’Addario C, et al. (2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One. 7: e39186.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Benito C, et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively over-expressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J. Neurosci. 23:11136–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Solas M, Francis PT, Franco R, Ramirez MJ. (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol. Aging. 34:805–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25:1904–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Martin-Moreno AM, et al. (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation. 9: 8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Aso E, Juves S, Maldonado R, Ferrer I. (2013) CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J. Alzheimers Dis. 35:847–58.CrossRefGoogle Scholar
  15. 15.
    Wu J, et al. (2013) Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging. 34:791–804.CrossRefPubMedGoogle Scholar
  16. 16.
    Zilka N, et al. Who fans the flames of Alzheimer’s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflammation. 9:47.Google Scholar
  17. 17.
    Cras P, Kawai M, Siedlak S, Perry G. (1991) Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. Brain Res. 558:312–4.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Serrano-Pozo A, et al. (2011) Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am. J. Pathol. 179:1373–84.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Li Y, Liu L, Barger SW, Griffin WS. (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23:1605–11.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yoshiyama Y, et al. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 53:337–51.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lee DC, et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J. Neuroinflammation. 7:56.Google Scholar
  22. 22.
    Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclindependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J. Neurosci. 25:8843–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Acker CM, Forest SK, Zinkowski R, Davies P, d’Abramo C. (2013) Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol. Aging. 34:338–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Buckley NE, et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396:141–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Buckley NE. (2008) The peripheral cannabinoid receptor knockout mice: an update. Br. J. Pharmacol. 153:309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Maresz K, et al. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13:492–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Karsak M, et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 316:1494–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Palazuelos J, et al. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain. 132:3152–64.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mucke L, et al. (2000) High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:4050–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Dudal S, et al. (2004) Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging. 25:861–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Kawarabayashi T, et al. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J. Neurosci. 21:372–81.CrossRefPubMedGoogle Scholar
  32. 32.
    Vingtdeux V, et al. (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285:9100–13.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kaczmarek E, Gorna A, Majewski P. (2004) Techniques of image analysis for quantitative immunohistochemistry. Rocz. Akad. Med. Bialymst. 49 Suppl 1:155–8.PubMedGoogle Scholar
  34. 34.
    Turner RS. (2001) Alzheimer’s disease in man and transgenic mice: females at higher risk. Am. J. Pathol. 158:797–801.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ehrhart J, et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation. 2: 29.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wang J, Dickson DW, Trojanowski JQ, Lee VM. (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp. Neurol. 158:328–37.CrossRefPubMedGoogle Scholar
  37. 37.
    Yin YI, et al. (2007) γ-Secretase substrate concentration modulates the Abeta42/Abeta40 ratio: implications for Alzheimer disease. J. Biol. Chem. 282:23639–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Cabral GA, Dove Pettit DA. (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 83:116–23.CrossRefPubMedGoogle Scholar
  39. 39.
    Klein TW, Friedman H, Specter S. (1998) Marijuana, immunity and infection. J. Neuroimmunol. 83:102–15.CrossRefPubMedGoogle Scholar
  40. 40.
    Klein TW. (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5:400–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Ito D, et al. (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 57:1–9.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lee DC, et al. (2013) Review: experimental manipulations of microglia in mouse models of Alzheimer’s pathology: activation reduces amyloid but hastens tau pathology. Neuropathol. Appl. Neurobiol. 39:69–85.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bellucci A, et al. (2007) Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol. Dis. 27:328–38.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Koppel J, Davies P. (2008) Targeting the endocannabinoid system in Alzheimer’s disease. J. Alzheimers Dis. 15:495–504.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Ehrhart J, et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation. 2: 29.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 43:321–32.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Oddo S, et al. (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281:39413–23.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Jeremy Koppel
    • 1
    • 4
  • Valerie Vingtdeux
    • 1
  • Philippe Marambaud
    • 1
  • Cristina d’Abramo
    • 1
  • Heidy Jimenez
    • 1
  • Mark Stauber
    • 2
  • Rachel Friedman
    • 3
  • Peter Davies
    • 1
  1. 1.Litwin-Zucker Research CenterFeinstein Institute for Medical Research, North-Shore Long Island Jewish Health SystemManhassetUSA
  2. 2.Yeshiva UniversityNew YorkUSA
  3. 3.Queens CollegeNew YorkUSA
  4. 4.ManhassetUSA

Personalised recommendations